Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Geoffrey Liu

Showing results (341-350 of 574) with videos related to

Pageof 58
Sort By:
Clinical Lung Cancer|June 2, 2024
Immediate Versus Deferred Systemic Therapy in Patients With MesotheliomaSabine Schmid, Luna Zhan, Miguel Garcia, et al.
Oncotarget|March 31, 2016
A window of opportunity study of potential tumor and soluble biomarkers of response to preoperative erlotinib in early stage non-small cell lung cancerAdrian G Sacher, Lisa W Le, Humberto Lara-Guerra, et al.
Clinical Lung Cancer|May 12, 2020
Early Detection of Multiple Resistance Mechanisms by ctDNA Profiling in a Patient With EGFR-mutant Lung Adenocarcinoma Treated With OsimertinibSabine Schmid, Erin L Stewart, Sebastiao N Martins-Filho, et al.
Cancer Epidemiology|January 16, 2017
Early adulthood body mass index, cumulative smoking, and esophageal adenocarcinoma survivalAnna Spreafico, Linda Coate, Rihong Zhai, et al.
Oncotarget|April 22, 2017
Association of BRM promoter polymorphisms and esophageal adenocarcinoma outcomeGrzegorz J Korpanty, Lawson Eng, Xin Qiu, et al.
JTO Clinical and Research Reports|September 25, 2023
Programmed Cell Death Protein 1 Inhibitors and MET Targeted Therapies in NSCLC With <i>MET</i> Exon 14 Skipping Mutations: Efficacy and Toxicity as Sequential TherapiesSally C M Lau, Kirstin Perdrizet, Andrea S Fung, et al.
Nature Communications|November 29, 2014
Integrated omic analysis of lung cancer reveals metabolism proteome signatures with prognostic impactLei Li, Yuhong Wei, Christine To, et al.
The Lancet. Oncology|June 13, 2017
Ceritinib versus chemotherapy in patients with ALK-rearranged non-small-cell lung cancer previously given chemotherapy and crizotinib (ASCEND-5): a randomised, controlled, open-label, phase 3 trialAlice T Shaw, Tae Min Kim, Lucio Crinò, et al.
BMC Cancer|May 19, 2011
Genetic variation in DNA-repair pathways and response to radiochemotherapy in esophageal adenocarcinoma: a retrospective cohort study of the Eastern Cooperative Oncology GroupHarry H Yoon, Paul J Catalano, Kathleen M Murphy, et al.
BMJ Open|January 20, 2019
Health-related quality of life and anxiety in the PAN-CAN lung cancer screening cohortNiloofar Taghizadeh, Alain Tremblay, Sonya Cressman, et al.
Pageof 58

Showing results (341-350 of 574) with videos related to

Sort By:
Pageof 58
Clinical Lung Cancer|June 2, 2024
Immediate Versus Deferred Systemic Therapy in Patients With MesotheliomaSabine Schmid, Luna Zhan, Miguel Garcia, et al.
Oncotarget|March 31, 2016
A window of opportunity study of potential tumor and soluble biomarkers of response to preoperative erlotinib in early stage non-small cell lung cancerAdrian G Sacher, Lisa W Le, Humberto Lara-Guerra, et al.
Clinical Lung Cancer|May 12, 2020
Early Detection of Multiple Resistance Mechanisms by ctDNA Profiling in a Patient With EGFR-mutant Lung Adenocarcinoma Treated With OsimertinibSabine Schmid, Erin L Stewart, Sebastiao N Martins-Filho, et al.
Cancer Epidemiology|January 16, 2017
Early adulthood body mass index, cumulative smoking, and esophageal adenocarcinoma survivalAnna Spreafico, Linda Coate, Rihong Zhai, et al.
Oncotarget|April 22, 2017
Association of BRM promoter polymorphisms and esophageal adenocarcinoma outcomeGrzegorz J Korpanty, Lawson Eng, Xin Qiu, et al.
JTO Clinical and Research Reports|September 25, 2023
Programmed Cell Death Protein 1 Inhibitors and MET Targeted Therapies in NSCLC With <i>MET</i> Exon 14 Skipping Mutations: Efficacy and Toxicity as Sequential TherapiesSally C M Lau, Kirstin Perdrizet, Andrea S Fung, et al.
Nature Communications|November 29, 2014
Integrated omic analysis of lung cancer reveals metabolism proteome signatures with prognostic impactLei Li, Yuhong Wei, Christine To, et al.
The Lancet. Oncology|June 13, 2017
Ceritinib versus chemotherapy in patients with ALK-rearranged non-small-cell lung cancer previously given chemotherapy and crizotinib (ASCEND-5): a randomised, controlled, open-label, phase 3 trialAlice T Shaw, Tae Min Kim, Lucio Crinò, et al.
BMC Cancer|May 19, 2011
Genetic variation in DNA-repair pathways and response to radiochemotherapy in esophageal adenocarcinoma: a retrospective cohort study of the Eastern Cooperative Oncology GroupHarry H Yoon, Paul J Catalano, Kathleen M Murphy, et al.
BMJ Open|January 20, 2019
Health-related quality of life and anxiety in the PAN-CAN lung cancer screening cohortNiloofar Taghizadeh, Alain Tremblay, Sonya Cressman, et al.
Pageof 58